Spyre Therapeutics
SYRE
SYRE
77 hedge funds and large institutions have $137M invested in Spyre Therapeutics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 9 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
77
Holders Change
+6
Holders Change %
+8.45%
% of All Funds
1.68%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
16
Increased
35
Reduced
9
Closed
8
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$1K
Top Buyers
1 |
BlackRock
New York
|
+$2.5M |
2 |
![]()
Marshall Wace
London,
United Kingdom
|
+$1.94M |
3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.37M |
4 |
AG
Artal Group
Luxembourg
|
+$1.16M |
5 |
State Street
Boston,
Massachusetts
|
+$954K |
Top Sellers
1 |
Jennison Associates
New York
|
-$6.25M |
2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.4M |
3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.19M |
4 |
Citadel Advisors
Miami,
Florida
|
-$611K |
5 |
MWNA
Marshall Wace North America
New York
|
-$179K |